Maxima Injection 40 mg/vial contains Esomeprazole, a proton pump inhibitor (PPI) formulated for intravenous administration. It is indicated for the short-term treatment of acid-related disorders when oral therapy is not appropriate or feasible. By effectively suppressing gastric acid secretion, Maxima Injection provides rapid symptom relief and supports mucosal healing in hospitalized or critically ill patients.

Esomeprazole is the S-isomer of omeprazole and offers enhanced acid control through selective inhibition of the gastric proton pump. The injectable form ensures reliable systemic exposure in patients who are unable to take oral medications due to severe illness, surgery, or gastrointestinal complications.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Proton Pump Inhibitor (PPI)

• Anti-ulcerant (Intravenous formulation)

Indications

Maxima Injection 40 mg/vial is indicated for:

• Gastroesophageal Reflux Disease (GERD) in patients unable to take oral therapy

• Healing of erosive esophagitis

• Short-term management of acid-related disorders

• Prevention of rebleeding following endoscopic treatment of peptic ulcer bleeding (as per clinical judgment)

• Zollinger-Ellison Syndrome and other pathological hypersecretory conditions

It is intended for short-term intravenous use, with transition to oral esomeprazole as soon as clinically appropriate.

Dosage & Administration

The recommended adult dose is 40 mg once daily administered by:

• Slow intravenous injection over at least 3 minutes, or

• Intravenous infusion over 10 to 30 minutes

Reconstitution:

• Add 5 ml of sterile Water for Injection (WFI) to the vial.

• Gently swirl to dissolve completely.

• Administer within 12 hours of reconstitution when stored at room temperature (below 30°C).

• Do not use if the solution contains visible particles.

Esomeprazole IV should not be administered simultaneously with other medications through the same intravenous line. Treatment should be switched to oral therapy as soon as the patient can tolerate it.

Pharmacology

Esomeprazole acts by specifically inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cell. This enzyme represents the final step in gastric acid production. By blocking this pathway, esomeprazole suppresses both basal and stimulated acid secretion.

Following intravenous administration, esomeprazole is rapidly distributed and is approximately 97% bound to plasma proteins. It is extensively metabolized in the liver by CYP2C19 and CYP3A4 enzymes into inactive metabolites. The plasma elimination half-life is approximately 1–1.5 hours. Around 80% of the administered dose is excreted in urine as inactive metabolites, with the remainder eliminated in feces.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Contraindications

Maxima Injection is contraindicated in patients with:

• Known hypersensitivity to esomeprazole or any component of the formulation

• Hypersensitivity to substituted benzimidazoles

Side Effects

Common adverse reactions may include:

• Headache

• Nausea

• Diarrhea

• Abdominal pain

• Constipation

• Flatulence

• Injection site reactions

Most side effects are mild and transient. Long-term safety profile is consistent with that of oral esomeprazole.

Precautions & Warnings

• Symptomatic response does not exclude gastric malignancy.

• Use caution in patients with severe hepatic impairment; dosage adjustment may be required.

• Monitor patients receiving prolonged therapy for potential vitamin B12 deficiency or hypomagnesemia.

• Not recommended for pediatric patients due to limited safety data.

Pregnancy & Lactation

Adequate human studies are lacking. Use during pregnancy only if clearly needed. As it is not known whether esomeprazole is excreted in breast milk, breastfeeding should be discontinued if treatment is essential.

Storage Conditions

Store below 30°C in a dry place. Protect from light and moisture. Keep out of reach of children.